Fusion Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
FUSN Fusion Pharmaceuticals Inc
RDUS Schnitzer Steel Industries Inc
ALEC Alector Inc
LZM Lifezone Metals Ltd
LMRMF Lomiko Metals Inc
SOXL Direxion Daily Semiconductor Bull 3X Shares
OXSQ Oxford Square Capital Corp
BAER Bridger Aerospace Group Holdings Inc
CMRA Comera Life Sciences Holdings Inc
SY So-Young International Inc

Health Care : Biotechnology | Small Cap Value
Based in Canada
Company profile

Fusion Pharmaceuticals Inc. is a clinical-stage oncology company. The Company is focused on developing radiopharmaceuticals as precision medicines. It has developed its Targeted Alpha Therapies (TAT), platform to enable it to connect alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha particle payloads to tumors. The TAT platform is underpinned by its ability to radiolabel various classes of targeting molecules, its research and insights into the underlying chemistry and biology of alpha emitting radiopharmaceuticals, its differentiated capabilities in target identification, candidate generation, manufacturing and supply chain, its Fast-Clear linker technology used in conjunction with antibody-based targeting molecules, and development of imaging agents. Its clinical portfolio includes FPI-2265, FPI-1434 and FPI-2059. FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer in a Phase 2 trial.

Day's Change
-0.155 (-6.09%)
B/A Size
Day's High
Day's Low

Today's volume of 23,061 shares is on pace to be in-line with FUSN's 10-day average volume of 28,131 shares.


U.S. Bancorp Stock Underperforms Thursday When Compared To Competitors

5:31 pm ET May 11, 2023 (MarketWatch)

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of U.S. Bancorp (USB) slipped 1.80% to $28.92 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.17% to 4,130.62 and Dow Jones Industrial Average falling 0.66% to 33,309.51.

This was the stock's second consecutive day of losses.

U.S. Bancorp closed $24.45 short of its 52-week high ($53.37), which the company reached on May 31st.

The stock demonstrated a mixed performance when compared to some of its competitors Thursday, as Bank of America Corp. (BAC) rose 0.26% to $27.39, Great Southern Bancorp Inc. (GSBC) fell 2.63% to $48.93, and Wells Fargo & Co. (WFC) rose 0.13% to $38.33.

Trading volume (16.4 M) remained 4.3 million below its 50-day average volume of 20.7 M.

Data source: Dow Jones Market Data, FactSet. Data compiled May 11, 2023.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.


(END) Dow Jones Newswires

May 11, 2023 17:31 ET (21:31 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.